Business ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Weight Loss Drugs

Eli Lilly Briefly Hits $1 Trillion as GLP-1 Boom Spurs Fresh Analyst Targets

Analyst upgrades highlight expectations for policy-driven access gains, with an oral GLP-1 filing seen as the next catalyst.

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial